Journal of the Formosan Medical Association
Volume 109, Issue 5 , Pages 362-368, May 2010

Characteristics and Risk Factors of Oxaliplatin-related Hypersensitivity Reactions

  • Yu-Yun Shao

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Department of Oncology, National Taiwan University Hospital Yun-Lin Branch, Yunlin, Taiwan
    • ,
  • Fu-Chang Hu

      Affiliations

    • Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Jin-Tung Liang

      Affiliations

    • Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Wen-Tzu Chiu

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Ann-Lii Cheng

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Chih-Hsin Yang

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Chih-Hsin Yang, Department of Oncology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10002, Taiwan

Received 31 March 2009; received in revised form 16 August 2009; accepted 25 August 2009.

Article Outline

Background/Purpose

Hypersensitivity reactions during oxaliplatin infusion are a major problem associated with its use. In this study, we investigated the characteristics and risk factors of these events.

Methods

All patients who had received oxaliplatin in outpatient settings from January 2006 to March 2007 in a medical center were enrolled in this retrospective study. All the oxaliplatin infusions were reviewed. Manifestations of hypersensitivity reactions and clinicopathological variables were collected from medical records.

Results

Three hundred and eighty-three patients with 3648 oxaliplatin infusions were reviewed. Forty-seven patients (12.7%) developed hypersensitivity reactions, which occurred after a median of 10 infusions. The median time of onset from start of infusion was 40 minutes. Most presentations (90.7%) were mild to moderate, but rechallenge with oxaliplatin led to a high chance of further reactions (71.4%). Cutaneous symptoms were the most prevalent manifestation, followed by respiratory symptoms. With each repeated infusion, the incidence of hypersensitivity reactions increased. Higher oxaliplatin dose per infusion was an independent risk factor for such reactions.

Conclusion

Patients treated with oxaliplatin for an extended period have a greater risk of oxaliplatin-related hypersensitivity reactions.

Key Words:  chemotherapy , drug hypersensitivity , oxaliplatin

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. de Gramont A , Vignoud J , Tournigand C , et al.   Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer . Eur J Cancer . 1997;33:214–219
  2. Thomas RR , Quinn MG , Schuler B , et al.   Hypersensitivity and idiosyncratic reactions to oxaliplatin . Cancer . 2003;97:2301–2307
  3. Andre T , Boni C , Mounedji-Boudiaf L , et al.   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer . N Engl J Med . 2004;350:2343–2351
  4. Brandi G , Pantaleo MA , Galli C , et al.   Hypersensitivity reactions related to oxaliplatin (OHP) . Br J Cancer . 2003;89:477–481
  5. Gowda A , Goel R , Berdzik J , et al.   Hypersensitivity reactions to oxaliplatin: incidence and management . Oncology (Williston Park) . 2004;18:1671–1684
  6. Kim BH , Bradley T , Tai J , et al.   Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review . Oncology . 2009;76:231–238
  7. Polyzos A , Tsavaris N , Gogas H , et al.   Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience . Oncology . 2009;76:36–41
  8. Shao YY , Hong RL . Fatal thrombocytopenia after oxaliplatin-based chemotherapy . Anticancer Res . 2008;28:3115–3117
  9. Stahl M , Koster W , Wilke H . Reaction after oxaliplatin-with corticosteroids? . Ann Oncol . 2001;12:874
  10. Siu SW , Chan RT , Au GK . Hypersensitivity reactions to ox-aliplatin: experience in a single institute . Ann Oncol . 2006;17:259–261
  11. Lenz G , Hacker UT , Kern W , et al.   Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution . Anticancer Drugs . 2003;14:731–733
  12. Lee MY , Yang MH , Liu JH , et al.   Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication . Support Care Cancer . 2007;15:89–93
  13. National Cancer Institute U.S.  . Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 . Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm 2006; [Date accessed: Mar 1, 2009]
  14. de Vries RS , Mattijssen EJ , van Sorge AA . Serious delayed hypersensitivity reaction to oxaliplatin . Ann Oncol . 2006;17:1723–1724
  15. Saunders MP , Denton CP , O'Brien ME , et al.   Hypersensitivity reactions to cisplatin and carboplatin-a report on six cases . Ann Oncol . 1992;3:574–576
  16. Onoyama Y , Umezu T , Kuriaki Y , et al.   Hypersensitivity reactions to cisplatin following multiple uncomplicated courses: a report on two cases . J Obstet Gynaecol Res . 1997;23:347–352
  17. Khan A , Hill JM , Grater W , et al.   Atopic hypersensitivity to cis-dichlorodiammineplatinum(II) and other platinum complexes . Cancer Res . 1975;35:2766–2770
  18. Sliesoraitis S , Chikhale PJ . Carboplatin hypersensitivity . Int J Gynecol Cancer . 2005;15:13–18
  19. Meyer L , Zuberbier T , Worm M , et al.   Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule . J Clin Oncol . 2002;20:1146–1147
  20. Gammon D , Bhargava P , McCormick MJ . Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol . Oncologist . 2004;9:546–549
  21. Lim KH , Huang MJ , Lin HC , et al.   Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule . Anticancer Drugs . 2004;15:605–607
  22. Mis L , Fernando NH , Hurwitz HI , et al.   Successful desensitization to oxaliplatin . Ann Pharmacother . 2005;39:966–969
  23. Edmondson DA , Gruling BJ , Urmanski AM , et al.   Oxaliplatin hypersensitivity: case report and successful repeat desensitization . Am J Ther . 2007;14:116–118

PII: S0929-6646(10)60064-2

doi:10.1016/S0929-6646(10)60064-2

Journal of the Formosan Medical Association
Volume 109, Issue 5 , Pages 362-368, May 2010

Article Tools